ストックスクリーナーアプリを入手
1.10
2.65%
-0.03
Spero Therapeutics Inc (SPRO) 最新ニュース
Spero Therapeutics grants 556,000 awards to new hires for Spero Therapeutics stock - ad-hoc-news.de
Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight - GlobeNewswire Inc.
Discover Spero Therapeutics Alongside Two Promising Penny Stocks - simplywall.st
Spero Therapeutics (NasdaqGS:SPRO) Stock Forecast & Analyst Predictions - Simply Wall Street
SPROSpero Therapeutics Inc Short Interest - Finviz
Spero Therapeutics, Inc. SEC Filing (Sep 11, 2026) - Stock Titan
Spero Therapeutics (SPRO) 10K Form and Latest SEC Filings 2026 - marketbeat.com
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New employees get stock awards at Spero, unlocking from 2027 - Stock Titan
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - marketscreener.com
A biotech CEO will speak in New York Sept. 15. Spero will stream it. - Stock Titan
Spero Therapeutics stock gains on small-cap biotech interest - ad-hoc-news.de
Resilient Spero Therapeutics stock prepares up to $300 million shelf as Nasdaq price holds around $1 - ad-hoc-news.de
Spero Therapeutics Launches New ATM Program With Jefferies for Up to $100 Million - TradingView
Spero TherapeuticsMay Offer Up To $300 Million In SecuritiesSEC Filing - tradingview.com
Spero Therapeutics Inc. (SPRO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Spero Therapeutics Inc. (SPRO) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Spero Therapeutics Company Profile & Introduction - Moomoo
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript - AOL.com
Alphabet Inc. Makes New Investment in Spero Therapeutics, Inc. $SPRO - MarketBeat
Spero Therapeutics, Inc.: Shareholders Board Members Managers and Company Profile | US84833T1034 - marketscreener.com
Diluted shares outstanding of Spero Therapeutics, Inc. – BIVA:SPRO - TradingView
Long term debt to total assets ratio of Spero Therapeutics, Inc. – BMV:SPRO - TradingView
Net current asset value per share of Spero Therapeutics, Inc. – BMV:SPRO - TradingView
Spero Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ... - Yahoo Finance
Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights - GuruFocus
SPRO Looks 14.8% Overvalued on GF Value™ as FDA Approval Spurs I - GuruFocus
Spero Therapeutics Q2 Earnings Call Highlights - MarketBeat
Spero Therapeutics Q2 Earnings Call Highlights - Yahoo Finance
SPRO: FDA approval, immunology pivot, and $105M financing extend cash runway into 2029 - TradingView
Earnings call transcript: Spero Therapeutics posts small q2 2026 EPS beat - Investing.com
Spero Therapeutics (NASDAQ:SPRO) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Is Spero Therapeutics Inc (SPRO) a Smart Investment Post Q2 Earnings? GF Score: 69/100, 13.3% Overvalued - GuruFocus
SPRO: FDA approval of Utebzi and $105M financing position the company for long-term growth - tradingview.com
Spero Therapeutics 2Q 2026: Revenue $0M, EPS $(0.16) — 10-Q Summary - TradingView
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update - The Manila Times
Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
KLRS Stock Price and Chart — NASDAQ:KLRS - TradingView
Spero Therapeutics (SPRO) Slips to $1.26: Stock Holds Tight Range Between $1.20 Support and $1.32 ResistanceThematic ETF Flow - vinanet.vn
Spero Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Equity awards for Spero Therapeutics (SPRO) chief medical officer - Stock Titan
Spero Therapeutics CMO Debra Zack files initial beneficial ownership statement - Bitget
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
SPRO Q2'26 Earnings: EPS estimate is (0.17) USD - TradingView
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 - The Manila Times
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 - marketscreener.com
4.22%
大文字化:
|
ボリューム (24 時間):